RESEARCH ROUND-UP |
research round-up
COMBINED SUPERFICIAL & DEEP FRACTIONAL SKIN TREATMENT FOR PHOTODAMAGED SKIN—A PROSPECTIVE CLINICAL TRIAL
Gold MH, Biron JA. J Cosmet Laser Ther 2012; 14(3): 124–32
Fractional CO2 B
PHARMACOKINETICS AND DISTRIBUTION OF FLUVOXAMINE TO THE BRAIN IN RATS UNDER OXIDATIVE STRESS
Kobuchi S, Fukushima K, Ito Y, Sugioka N, Takada K. Free Radic Res 2012; 46(7): 831–41
fluvoxamine (FLV), particularly on FLV distribution in the plasma, were studied in ferric-nitrilotriacetate-induced OS rat models (OS rats). The study protocol involved a continuous FLV infusion (25.0 m g/kg/min). The resulting mean plasma FLV concentration measured in steady state OS rats was 0.13 ± 0.01 m g/mL, which was significantly lower than plasma concentrations measured in control rats (0.19 ± 0.01 m g/mL). Moreover, the mean FLV concentration in the OS rat brain (0.51 ± 0.08 m g/g) was determined to be approximately half the concentration in control rat brains (0.95 ± 0.11 m g/g). The FLV concentrations in both the unbound fraction of plasma and erythrocytes of OS rats were significantly greater than that of control rats. These results suggest the potential attenuation of FLVÕs pharmacological effects in patients under OS.
T 52 ❚
HE EFFECTS OF OXIDATIVE STRESS (OS) on the pharmacokinetics of
ACKGROUND AND OBJECTIVES. Deep microthermal zones targeted by lasers stimulate fibroblast
activity, whereas superficial microthermal zones target the epidermal layer pigment. The new combination modality enables targeting both deep and superficial disorders. The study is designed to evaluate the improvement in photodamage and determine downtime. Materials and methods. This IRB approved study was aimed to evaluate histology phenotype of combined deep and superficial
skin resurfacing. A 120-micron, focused CO2 laser beam was used to create both deep and superficial fractional skin resurfacing using ultrapulse and continuous wave laser modes, respectively. Fifteen patients (skin types II–V) underwent combined treatment and returned for assessment at 1 week, 1 and 3 months to evaluate the clinical outcome. Additional histological analysis of human tissue was performed to elucidate the combined impact on tissue. Results. Pre-clinical histologies demonstrated the ability to achieve fractional discrete 1.3-mm-diameter spots of superficial ablation with a uniform shallow and narrow area of coagulation while maintaining the deep, fractional 120-micron-ablation spot capabilities. Histologies of the human tissue confirmed the ability to control both superficial and deep fractional treatment using a single handpiece. Pigmentation was greatly reduced at the 1 month follow-up with significant textural improvement. No
July/August 2012 |
prime-journal.com B
A round-up of the most recently published academic articles and research
unexpected AEs or SAEs were reported. Conclusion. The new modality enables combined superficial and deep fractional impact and improvements that are demonstrated at both the phenotype and tissue level.
TOPICAL 5% TRANEXAMIC ACID FOR THE TREATMENT OF MELASMA IN ASIANS: A DOUBLE- BLIND RANDOMIZED CONTROLLED CLINICAL TRIAL
Na Ayuthaya PK, Niumphradit N, Manosroi A, Nakakes A. J Cosmet Laser Ther 2012; 14(3): 150–4
ACKGROUND: TOPICAL TRANEXAMIC acid has been claimed to lighten melasma
without serious adverse effects. However, controlled studies assessing the efficacy and safety of topical tranexamic acid (TA) for the treatment of melasma is limited. Objective: To assess in a double blind, randomized, prospective study, the efficacy of topical 5% tranexamic acid versus vehicle for treatment of melasma. Methods: Twenty-three women with bilateral epidermal melasma enrolled in a split-face trial lasting 12 weeks. Patients blindly applied topical 5% tranexamic acid and its vehicle, to the designated sides of the face twice daily in addition to the assigned sunscreen each morning. Pigmentation and erythema were measured objectively using a mexameter and Melasma Area and Severity Index (MASI), in addition to physician and patient global assessments. Results: Twenty-one patients completed the study. Eighteen out of twenty-three patients (78.2%) showed decrease in the melanin index on either or both sides of the face by the end of
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84